362 related articles for article (PubMed ID: 27754406)
1. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
[TBL] [Abstract][Full Text] [Related]
2. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
5. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
6. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
7. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
8. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
9. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
11. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease.
Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R
Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of chitosan oligosaccharides on β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in HEK293 APPswe cells.
Dai X; Chang P; Li X; Gao Z; Sun Y
Neurosci Lett; 2018 Feb; 665():80-85. PubMed ID: 29175631
[TBL] [Abstract][Full Text] [Related]
14. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
15. Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity.
Durairajan SSK; Chirasani VR; Shetty SG; Iyaswamy A; Malampati S; Song J; Liu L; Huang J; Senapati S; Li M
Curr Alzheimer Res; 2017; 14(11):1229-1237. PubMed ID: 28413985
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells.
Chen LM; Lin ZY; Zhu YG; Lin N; Zhang J; Pan XD; Chen XC
Eur J Pharmacol; 2012 Jan; 675(1-3):15-21. PubMed ID: 22166376
[TBL] [Abstract][Full Text] [Related]
17. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
18. Melatonin regulates the transcription of βAPP-cleaving secretases mediated through melatonin receptors in human neuroblastoma SH-SY5Y cells.
Panmanee J; Nopparat C; Chavanich N; Shukla M; Mukda S; Song W; Vincent B; Govitrapong P
J Pineal Res; 2015 Oct; 59(3):308-20. PubMed ID: 26123100
[TBL] [Abstract][Full Text] [Related]
19. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
20. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Chen CH; Zhou W; Liu S; Deng Y; Cai F; Tone M; Tone Y; Tong Y; Song W
Int J Neuropsychopharmacol; 2012 Feb; 15(1):77-90. PubMed ID: 21329555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
